CTOs on the Move

Stealth BioTherapeutics

www.stealthbt.com

 
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stealthbt.com
  • 275 Grove Street Ste. 3-107
    Newton, MA USA 02466
  • Phone: 617.600.6888

Executives

Name Title Contact Details

Funding

Stealth BioTherapeutics raised $100M on 06/18/2018
Stealth BioTherapeutics raised $20M on 04/13/2020
Stealth BioTherapeutics raised $30M on 05/17/2021

Similar Companies

Renalytix

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Creo

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

VenatoRx

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company has also been awarded a contract from the NIH and funding from the Wellcome Trust to advance the company’s product candidates.

ZYTO Corporation

ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.